Resources
Learn more about EvaThera, MTTI, and the future of radiopharmaceuticals.
Resources
Learn more about EvaThera, MTTI, and the future of radiopharmaceuticals.
![](https://evathera.com/wp-content/uploads/2021/06/Section-3-image-Grande-1024x548.jpg)
![](https://evathera.com/wp-content/uploads/2021/06/icondef.png)
EvaThera Brochure
Innovative, therapeutic, and diagnostic targeted radiopharmaceuticals filling critical gaps in oncologic care.
![](https://evathera.com/wp-content/uploads/2021/06/icondef.png)
The EvaThera Story
EvaThera Theranostics are a new generation of Evans Blue-based molecules with strong affinity for albumin.
![](https://evathera.com/wp-content/uploads/2021/06/icondef.png)
![](https://evathera.com/wp-content/uploads/2021/06/icondef.png)
3 year study shows 86% disease control rate
Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors
![](https://evathera.com/wp-content/uploads/2021/06/icondef.png)
EBTATE for Imaging and Treatment of Thyroid Cancer
177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer
![](https://evathera.com/wp-content/uploads/2021/06/icondef.png)
EBTATE Reduces Tumor Size in Patients with NETs
Response to Single Low-dose 177Lu-DOTA-EB-TATE Treatment in Patients with Advanced Neuroendocrine Neoplasm: A Prospective Pilot Study.
![](https://evathera.com/wp-content/uploads/2021/06/icondef.png)
EBTATE safety and efficacy in patients with NETs
Peptide Receptor Radionuclide Therapy of Late-stage Neuroendocrine Tumor Patients with Multiple Cycles of 177Lu-DOTA-EB-TATE
![](https://evathera.com/wp-content/uploads/2021/06/icondef.png)
SNMMI 2022: EBTATE safety with and without Amino Acid Infusion
Evaluation of Safety, Biodistribution and Dosimetry of a long-Acting Radiolabeled Somatostatin Analogue 177Lu-DOTA-EB-TATE with and without Amino Acid Infusion
![](https://evathera.com/wp-content/uploads/2021/06/icondef.png)
Safety and Efficacy of 177Lu-DOTA-EB-TATE
New treatment proves more effective and less toxic for neuroendocrine tumor patients
![](https://evathera.com/wp-content/uploads/2021/06/icondef.png)
![](https://evathera.com/wp-content/uploads/2021/06/icondef.png)
EBRGD acts synergistically with checkpoint inhibitors
Integrin αvβ3-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy
![](https://evathera.com/wp-content/uploads/2021/06/icon.png)
Ready to learn more?
Reach out to us to learn more about EvaThera, MTTI, and the future of radiopharmaceuticals
![](https://evathera.com/wp-content/uploads/2021/06/LOGO-300x55.png)
© 2023 Molecular Targeting Technologies, INC. All Rights Reserved.
PHONE
610-738-7938
EMAIL